1BT Stock Chart & Stats
€1.09
-€0.18(-4.57%)
At close: 4:00 PM EDT
€1.09
-€0.18(-4.57%)
Day’s Range― - ―
52-Week Range€0.88 - €15.30
Previous CloseN/A
Volume0.00
Average Volume (3M)67.00
Market Cap
€14.78M
Enterprise Value€28.67
Total Cash (Recent Filing)€5.87M
Total Debt (Recent Filing)€641.00K
Price to Earnings (P/E)<0.1
Beta0.71
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)405.30
Shares Outstanding17,485,462
10 Day Avg. Volume52
30 Day Avg. Volume67
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€68.89Price Target Upside6220.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressRMAT status validates promising early clinical data and provides enhanced FDA engagement with a potentially expedited development path. Alongside the ongoing 182-patient Phase IIb trial, this could improve regulatory clarity and strengthen Allocetra’s competitive position over the next several quarters.
Low LeverageVery low leverage reduces fixed financial obligations and leaves more flexibility to direct resources toward clinical development. Compared with a heavily indebted biotech, Enlivex has less balance-sheet interest burden and potentially greater capacity to manage development uncertainty or pursue strategic funding.
Potential Capital AccessIf completed, the private placement would provide substantial funding for Allocetra development, debt repayment and treasury activities, extending financial capacity beyond immediate operating needs. The additional three-year option could also create further funding flexibility, although execution remains conditional.
Bears Say
No Operating RevenueThe absence of meaningful product revenue means Enlivex has not yet demonstrated commercial demand or an operating model that can fund itself. Continued large operating losses leave results dependent on clinical success, regulatory approval and future financing rather than recurring business cash inflows.
Persistent Cash BurnConsistently negative operating and free cash flow indicates that research and clinical activities continue to consume capital without internally generated funding. Until operating cash flow improves, Enlivex remains reliant on equity, debt or other external sources, creating ongoing financing and execution pressure.
Digital-asset ConcentrationA large RAIN-token treasury introduces material exposure to digital-asset price volatility alongside the clinical-stage biotechnology risk. This concentration can make balance-sheet value, liquidity and financing outcomes more sensitive to an external token ecosystem rather than to progress in Allocetra’s core therapeutic business.
Enlivex News
1BT FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was €0.88 and its highest was €15.30 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is €14.78M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is Apr 23, 2027 which is in 223 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on May 22, 2026. The company reported -€0.017 earnings per share for the quarter.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 17,485,462 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -€0.017 in its last earnings report. Following the earnings report the stock price went up 2.521%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in DE:1BT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
1BT Stock 12 Month Forecast
Average Price Target
€68.89
▲(6220.58% Upside)